New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:15 EDTSI, THLDThreshold Pharmaceuticals acquires [18F]HX4 from Siemens Healthcare
Threshold Pharmaceuticals (THLD) announced a global agreement with Siemens Healthcare (SI) to acquire its investigational agent [18F]HX4, a radiolabeled hypoxia Positron Emission Tomography, or PET, tracer. [18F]HX4 could potentially be used as a companion diagnostic to hypoxia-targeted therapeutics based on Threshold's drug discovery platform. Threshold initially intends to develop [18F]HX4 to determine a patient's tumor hypoxia profile, which may identify patients who will best respond to Threshold's hypoxia-targeted therapeutics. Under the terms of the agreement, Siemens will transfer ownership and existing preclinical, clinical and manufacturing data related to [18F]HX4 to Threshold.
News For THLD;SI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
November 13, 2014
07:10 EDTTHLDSociety for NeuroOncology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use